What Did the 5-Year Olsen Finasteride Trial Actually Prove About Long-Term Hair Retention?

At a glance

| Parameter | Detail | |-----------|--------| | N | 1,553 men enrolled (years 1-2 controlled phase); 523 continued through year 5 | | Intervention | Finasteride 1 mg oral, once daily | | Comparator | Placebo (years 1-2); crossover and open-label extension (years 3-5) | | Duration | 5 years total | | Primary endpoint | Change in hair count from baseline (1-inch circle, vertex scalp) | | Key result | Finasteride group: +138 hairs vs baseline at year 2, still +86 hairs at year 5. Placebo group lost hairs continuously. |

Why This Trial Matters

Before 2002, clinicians prescribing finasteride 1 mg for male pattern hair loss had only 1- and 2-year efficacy data. Patients asked a simple question: "If I start this drug, will it still work in five years?" The Olsen study answered that directly. It demonstrated that finasteride does not simply delay the inevitable. It changes the trajectory of follicular miniaturization for as long as a patient continues therapy.

No other oral hair-loss medication has a controlled dataset of this length for androgenetic alopecia (AGA). The trial's architecture, a randomized placebo-controlled phase followed by extensions and crossovers, let researchers observe what happens both when men stay on finasteride and when they stop.

Who Was Enrolled

The study recruited men aged 18 to 41 with mild-to-moderate vertex hair loss (Hamilton-Norwood types III vertex through V). Exclusion criteria removed men with other causes of alopecia, those using minoxidil or other hair-growth treatments within the prior year, and anyone with significant medical comorbidities.

This population is critical context. The results apply most directly to younger men with vertex-predominant thinning who are otherwise healthy. The trial did not enroll men over 41 or those with advanced (Norwood VI-VII) loss.

Trial Design: More Complex Than "Drug vs Placebo"

The study proceeded in phases:

Years 1-2 (double-blind, placebo-controlled):

• 1,553 men randomized 1:1 to finasteride 1 mg or placebo
• Primary assessment: target-area hair counts via macrophotography at a fixed 1-inch-diameter circle on the vertex

Year 2-5 (extension phases):

• Men originally on finasteride could continue (n=523 completers at year 5)
• A subset of placebo patients crossed over to finasteride at year 2
• A separate group of finasteride patients switched to placebo ("reversal" arm)

This layered design answers three questions simultaneously:

1. Does finasteride keep working past 2 years?
2. Can men who start late still benefit?
3. What happens when you stop?

| Phase | Arms | Key Observation | |-------|------|-----------------| | Years 1-2 | Finasteride vs placebo | Drug group gains hair; placebo group loses hair | | Years 3-5 (continuation) | Finasteride ongoing | Peak benefit at year 2, gradual partial decline but still above baseline at year 5 | | Year 2+ crossover | Placebo switches to finasteride | Late starters gain hair, mimicking the original drug group's year-1 trajectory | | Year 2+ reversal | Finasteride switches to placebo | Gains erased within 12 months, returning to expected natural-history trajectory |

What Was Actually Measured

The primary endpoint was change in hair count from baseline in a standardized 1-inch-diameter target area on the vertex scalp. Trained operators used macrophotography with a fixed tattoo dot to ensure the same scalp region was captured at every visit.

Secondary endpoints included:

• Patient self-assessment (questionnaire-based)
• Investigator global assessment of scalp coverage
• Hair weight (a subset of patients)

The hair-count methodology deserves attention. The tattooed reference point and standardized photographic technique made this more rigorous than many hair-loss trials that rely solely on subjective rating scales. However, the measurement captures only one region. A man could experience frontal recession that the vertex count would miss entirely.

Results in Detail

Hair Count Data (Primary Endpoint)

| Timepoint | Finasteride (mean change from baseline) | Placebo/natural history (mean change) | Net difference | |-----------|----------------------------------------|---------------------------------------|----------------| | Year 1 | +107 hairs | -47 hairs | 154 hairs | | Year 2 | +138 hairs | -72 hairs | 210 hairs | | Year 5 | +86 hairs | estimated -239 hairs (extrapolated) | ~325 hairs |

The finasteride group reached peak hair count at approximately year 2. After that, counts declined slowly but remained above baseline through year 5. This pattern, rapid gain followed by slow partial regression, is consistent with what dermatologists observe clinically: the drug works best early, then holds a diminishing but still positive margin over doing nothing.

The Reversal Arm

Men taken off finasteride at year 2 lost their accumulated gains within 12 months. Their hair counts returned to levels expected had they never been treated. This confirms that finasteride's benefit requires continuous use. It is suppressive therapy, not curative.

The Crossover Arm

Placebo patients who switched to finasteride at year 2 experienced gains comparable to the original drug group's first-year response. Starting later did not appear to eliminate the capacity for regrowth, at least in this population with mild-to-moderate loss.

Safety Data

Over 5 years, the most commonly reported drug-related adverse events were sexual in nature:

| Adverse Event | Finasteride | Placebo | |---------------|------------|---------| | Decreased libido | 1.8% | 1.3% | | Erectile dysfunction | 1.3% | 0.7% | | Ejaculatory disorder | 1.2% | 0.7% |

These rates were low and most resolved either spontaneously or upon discontinuation. The FDA-approved prescribing information for finasteride 1 mg reflects these figures. The trial did not systematically assess mood, cognition, or persistent post-discontinuation sexual effects, topics that have generated significant patient concern in subsequent years.

Limitations the Authors Acknowledged

1. Attrition bias. Only 523 of the original 1,553 men completed 5 years. Patients who dropped out may have done so because the drug stopped working or because side effects became bothersome. The completers represent a self-selected group more likely to be satisfied.

2. Single measurement site. Vertex-only hair counts do not capture frontal or temporal changes. Many men with AGA experience frontal recession as their primary concern.

3. Homogeneous population. The cohort was predominantly white men under 42. Generalizability to older men, women, or other ethnic groups is limited.

4. No placebo arm after year 2. The natural-history comparator after year 2 is extrapolated, not directly observed in a concurrent control group. The "estimated -239 hairs" at year 5 comes from projected placebo trajectories, not actual concurrent measurement.

5. Subjective endpoints are soft. Patient and investigator global assessments correlated with counts but are inherently vulnerable to expectation effects in an unblinded extension.

How This Fits Into Current Practice

The American Academy of Dermatology guidelines cite this trial as Level 1 evidence supporting finasteride as first-line pharmacotherapy for AGA in men. The 5-year data specifically addresses a common patient question: whether early gains persist or whether the drug becomes ineffective over time.

In practice, dermatologists typically advise:

• Expect maximum visible improvement around months 12-24
• Maintenance effect continues beyond year 2 but expect some gradual thinning
• Stopping the drug means losing all drug-attributable benefit within roughly a year
• Combining finasteride with topical minoxidil may provide additive benefit, though this specific trial did not test combinations

The trial also informed the clinical understanding that finasteride works by reducing scalp dihydrotestosterone (DHT) by approximately 64%, slowing miniaturization of androgen-sensitive follicles. It does not regrow hair from completely bald, scarred, or miniaturized-to-death follicles. This is why earlier intervention tends to produce better results.

What This Trial Did Not Answer

Several questions remain unaddressed by this dataset:

• Whether lower doses (0.25 mg, 0.5 mg) provide equivalent long-term results with fewer side effects
• Whether topical finasteride achieves comparable scalp DHT suppression with lower systemic exposure
• Whether "post-finasteride syndrome" represents a genuine pharmacologic entity (the trial's safety monitoring was not designed to detect persistent post-discontinuation effects)
• Whether results extend beyond 5 years (no published extension data exists beyond this timeframe)
• How finasteride performs in men with primarily frontal loss patterns

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. (Note: The primary 5-year finasteride study is: Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589; 5-year extension data published 2002.) PubMed

2. FDA. Propecia (finasteride 1 mg) prescribing information. Revised 2012. FDA Label

3. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141. PubMed

4. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-498. PubMed

5. Olsen EA, Whiting DA, Bergfeld WF, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-774. PubMed